ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Economy

Lupin aims to resolve quality issues highlighted by FDA in 12-15 months

Company shares tumble on concerns U.S. business would be hurt by FDA move

An employee inspects tablets as they move along the production line at a pharmaceutical plant of Lupin in Verna, in the western state of Goa, India on June 9.   © Reuters

MUMBAI (NewsRise) -- Lupin said it aims to resolve over next 12-15 months the quality issues raised by the U.S. Food and Drug Administration amid concerns the regulator's warning could hamper the company's prospects in its biggest market.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more